Healthcare Services

Vasomotor Menopausal Symptoms (VMS) Treatment Market Expected to Reach $26.47 Billion by 2030 at 7.1% CAGR

April 28, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Expected To Reach Based On Its 2026 Value?

The vasomotor menopausal symptoms (vms) treatment market has experienced significant growth in recent years. This market is anticipated to increase from $19.01 billion in 2025 to $20.16 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. The expansion observed in the historical period can be ascribed to the increasing prevalence of menopausal symptoms, the widespread utilization of hormone replacement therapy, expanding clinical research focused on neurotransmitter-based treatments, the broader availability of women’s health services, and improved access to specialty clinics.

The vasomotor menopausal symptoms (vms) treatment market is poised for robust expansion over the coming years, with its valuation projected to reach $26.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This anticipated growth is fueled by factors such as an escalating demand for non-hormonal treatment alternatives, heightened awareness regarding menopause-related health management, increasing investments dedicated to women’s health research, the expanding reach of telemedicine for treatment delivery, and advancements in next-generation VMS therapeutics. Key developments anticipated during this forecast period encompass the accelerating creation of non-hormonal therapies, a rising embrace of personalized menopause treatment plans, the growing utilization of digital health platforms for symptom management, the broadening scope of combination drug therapies, and an intensified focus on long-term safety profiles.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

What Primary Drivers Are Shaping The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Government programs focusing on women’s health during menopause are anticipated to drive the expansion of the vasomotor menopausal symptom’s treatment market in the future. These government efforts for menopausal well-being include financial support for groundbreaking research into the menopausal transition, disease prevention, and various pharmacological, clinical, and epidemiological facets. Such endeavors form a component of wider women’s health strategies that tackle a range of issues. To illustrate, in January 2023, the Government of New South Wales, an Australian government body, commenced a plan to allocate $40.3 million across four years (from 2022-2023 to 2025-2026) for establishing up to 16 novel programs aimed at women experiencing acute menopausal symptoms. Consequently, government actions promoting women’s health during menopause are stimulating the growth of the vasomotor menopausal symptom’s treatment market.

How Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Categorized Across Its Segment Groups?

The vasomotor menopausal symptoms (vms) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) By Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) By Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) By Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) By Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

What Trends Are Affecting The Growth Of The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Leading companies active in the vasomotor menopausal symptoms treatment market are developing products like Veozah and securing approvals to introduce new treatment options and address patients’ unmet medical requirements. The authorization of novel medications for menopause offers enhanced effectiveness and safety when contrasted with current therapies. For instance, in May 2023, Astellas Pharma Inc, a Japan-based pharmaceutical company, obtained approval for Veozah (fezolinetant) 45 mg once daily from the Food and Drug Administration (FDA), a US-based federal agency, for managing menopausal vasomotor symptoms (VMS), which vary from mild to severe. It stands as the first nonhormonal neurokinin 3 (NK3) receptor antagonist to receive authorization for treating menopausal-related VMS. This hormone-free option works by blocking a specific pathway in the brain involved in regulating these symptoms. It presents an alternative therapeutic choice for women experiencing such symptoms, particularly those who cannot or choose to avoid hormone therapy. The sanctioning of Veozah underscores its promise as an innovative medication for handling menopausal symptoms.

Which Firms Are Influencing Competition In The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc

Get The Full Vasomotor Menopausal Symptoms (VMS) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

Which Region Dominates The Vasomotor Menopausal Symptoms (VMS) Treatment Market By Market Share?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2025. The regions covered in the vasomotor menopausal symptoms (vms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Vasomotor Menopausal Symptoms (VMS) Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

Browse Through More Reports Similar to the Global Vasomotor Menopausal Symptoms (VMS) Treatment Market 2026, By The Business Research Company

Menopausal Hot Flashes Market Report 2026

https://www.thebusinessresearchcompany.com/report/menopausal-hot-flashes-global-market-report

Menopause Market Report

https://www.thebusinessresearchcompany.com/report/menopause-global-market-report

Vulvodynia Treatment Market Report

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795